Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: Safety and efficacy

Erdoğar, Nazlı; İskit, Alper B.; Eroğlu, Hakan; Sargon, Mustafa F.; Mungan, N.A.; Bilensoy, Erem

doi:10.1016/j.ijpharm.2014.05.014

Cited by 34 publications

(18 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1, nanoparticles restricted the uptake of mitomycin into systemic circulation after bladder instillation. Chitosan coated poly-ε-caprolactone nanoparticles of mitomycin extended the survival of rats with bladder tumor 83 . In another study delivery of docetaxel to bladder tumor was enhanced by mucoadhesive nanoparticles formed by hyperbranched polyglycerols 84 .…”

Section: Nanoparticlesmentioning

confidence: 97%

Advances in intravesical therapy for urinary tract disorders

Tyagi

Kashyap

Hensley

et al. 2015

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction Intravesical therapy is a valuable option in the clinical management of urinary tract disorders such as interstitial cystitis/ painful bladder syndrome (IC/PBS) and refractory overactive bladder. This review will cover the latest advances in this field using polymer and liposomes as delivery platform for drugs, protein and nucleic acids. Areas covered This review summarizes the significance of intravesical therapy for lower urinary tract disorders. The recent advancement of liposomes as a drug delivery platform for botulinum toxin, tacrolimus and small interfering RNA is discussed. The importance of polymers forming indwelling devices and hydrogels are also discussed, where all preparations improved efficacy parameters in rodent models. Clinical experience of treating IC/PBS with indwelling devices and liposomes are summarized and preclinical evidence about the downregulation of target gene expression in rodent bladder with liposomes complexed with siRNA is also reviewed. Expert opinion There have been several advances in the field of intravesical therapy for improving clinical outcomes. One of the most promising research avenues is the repurposing of drugs, given previously by other routes of administration, such as tacrolimus. Intravesical therapy also opens up novel therapeutic targets with improved efficacy and safety for underactive bladder.

show abstract

Section: Nanoparticlesmentioning

confidence: 97%

Advances in intravesical therapy for urinary tract disorders

Tyagi

Kashyap

Hensley

et al. 2015

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Nanoparticle-based drug delivery systems with cytotoxic agents of favorable size and capable of adhering to urothelium can potentially prolong the duration of action and decrease toxicity (Tyagi et al, 2016;Ding et al, 2019b). Erdogar et al (2014) designed a chitosan-and PCL-based core-shell nanoparticles to deliver mitomycin C, and evaluated the anti-tumor efficacy of the delivery system in bladder tumor model. The results indicated that the drug-loaded nanoparticles treatment group showed the longest survival rate compared to other groups.…”

Section: Nanoparticle-based Drug Delivery Systemsmentioning

confidence: 99%

Advances in Drug Delivery via Biodegradable Ureteral Stent for the Treatment of Upper Tract Urothelial Carcinoma

et al. 2020

View full text Add to dashboard Cite

Drug eluting ureteral stent is an effective means for local drug delivery to the urinary tract. It can potentially solve a variety of upper urinary tract problems, such as stent-related urinary tract infections and discomfort, ureteral stricture, and neoplastic diseases. However, the release of drug elutes on the surface of biostable stents is unsustainable and uncontrollable. With the development of biomaterial science, the emergence of biodegradable ureteral stents (BUSs) provides a new approach for local drug delivery in the urinary tract. The drugs can be continuously released in a controlled manner from a drug-eluting BUS, when the stent degrades. Especially for the delivery of anti-tumor drugs, the stents can obviously improve the therapeutic effectiveness of the drugs by prolonging the contact duration of the drug and tumor cells. In addition, a secondary stent removal procedure can be avoided. The purpose of this review article is to provide an overview of anti-tumor drug-eluting BUSs and discuss the biomaterials and drug delivery systems of BUS that are currently being developed to deliver anti-tumor drugs for upper tract urothelial carcinoma.

show abstract

“…Yaklaşık olarak her iki saatte bir mesanenin periyodik olarak boşaltılması gerekliliği bu faktörlerden en önemlisidir. Bu durumda ilaç idrarla hızlı bir şekilde dilüe olmakta, ilaç konsantrasyonunda görülen azalma sonucu tekrarlayan kateterizasyon gerekmektedir (5,6,8). Tekrarlanan intravezikal terapi idrara çıkma sırasında irritasyona sebep olmakta, mesanede fibrozis, enfeksiyon ve kemoterapötik ajanlar vücutta çeşitli toksik etkiler ortaya çıkarabilmektedir (5).…”

Section: İntravezikal Terapiunclassified

“…Diğer bir dezavantaj ise 'mesane permeabilite bariyeri' olarak adlandırılan ürotelyumun düşük permeabilitesidir (Şekil 1). Ürotelyum glikozaminoglikan müsin tabakasından oluşmakta ve bu tabaka derin dokulara moleküllerin mukozal absorpsiyonunu sınırlandırmakta aynı zamanda tedavi sırasında ilaçların mesane mukozasına adezyonunu önlemektedir (5,8). Günümüzde biyoadezif nanopartiküllerle mesanede ilaç taşıyıcı sistemlerin kalış süresini uzatmak, dokulardan ilaç alımını arttırmak ve permeabiliteyi düzeltmek için çeşitli teknolojik yaklaşımlar geliştirilmektedir.…”

Section: İntravezikal Terapiunclassified